While the development of durable cell and gene therapies represents extraordinary clinical value, the practical issues of financing cures continue to stand as an impediment to implementation. Will new payment approaches be an effective solution or will legislative issues, like MBP stand in the way of innovation and cures?
read full article ›An interesting perspective on how a community oncology practice did the unexpected – drove biosimilar utilization in oncology!
read full article ›Physician groups look to CMS to reverse the 2019 regulation allowing step therapy in Medicare Part B – implications of this change could be dramatic, especially with biosimilar utilization increasing under physician buy-and-bill models. Do you think physician groups would be willing to trade a flat admin fee in return for the end of step-edits…
read full article ›MUST READ: The Biden Administration just solved every problem in our economy and society with a bold new action plan – Step 1. reform drug pricing Step 2. See step 1. This can’t fail…
read full article ›Join us in celebrating Roger and all other named at the PharmaVoice 100 Celebration today!
read full article ›The NHS announced an inspiring new population health agreement today, making Novartis’ inclisiran available to 300,000+ patients with high cholesterol and a history of heart disease. This arrangement highlights the urgent need to apply alternative contracting solutions to ensure rapid patient access to innovative medicines- at scale.
read full article ›Some not so subtle points in the pipeline report from OptumRx: We’re watching... 1) orphan drugs carefully; and 2) how we can take advantage of even not-so-obvious ways of making them compete.
read full article ›ICER re-analyzed its original results on HAE which were based on trial results using real-world data from Aetion. Results: data showed significantly fewer baseline attacks meaning prophylactic therapies, per ICER, prevent fewer attacks than originally estimated…and that means the drugs’ economic value is lower.
read full article ›